Improving the Breadth of the Host’s Immune Response to Lassa Virus

In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolate...

Full description

Saved in:
Bibliographic Details
Published in:Pathogens (Basel) Vol. 7; no. 4; p. 84
Main Authors: Zapata, Juan, Medina-Moreno, Sandra, Guzmán-Cardozo, Camila, Salvato, Maria
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 28.10.2018
MDPI
Subjects:
Antigens
B cell anergy
broadly-neutralizing antibodies
Chemokines
conformational antigens
conserved antigens
cross-restriction
Cytokines
Dendritic cells
Disease
dominant and subdominant epitopes
Ebola virus
Edema
Epidemics
Fc-gamma receptors
focused immunity
Genetic diversity
Hearing loss
Immune response
Immune system
Infections
Influenza
Interferon
Lassa virus disease (LVD)
Medical research
mimicry
Pathogenesis
Pathogens
Public health
Review
vaccine breadth
Vaccines
Viral diseases
Viruses
West Africa
focused immunity
Lassa virus disease (LVD)
conserved antigens
broadly-neutralizing antibodies
vaccine breadth
mimicry
dominant and subdominant epitopes
conformational antigens
cross-restriction
B cell anergy
Fc-gamma receptors
ISSN:2076-0817, 2076-0817
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 2017, the global Coalition for Epidemic Preparedness (CEPI) declared Lassa virus disease to be one of the world’s foremost biothreats. In January 2018, World Health Organization experts met to address the Lassa biothreat. It was commonly recognized that the diversity of Lassa virus (LASV) isolated from West African patient samples was far greater than that of the Ebola isolates from the West African epidemic of 2013–2016. Thus, vaccines produced against Lassa virus disease face the added challenge that they must be broadly-protective against a wide variety of LASV. In this review, we discuss what is known about the immune response to Lassa infection. We also discuss the approaches used to make broadly-protective influenza vaccines and how they could be applied to developing broad vaccine coverage against LASV disease. Recent advances in AIDS research are also potentially applicable to the design of broadly-protective medical countermeasures against LASV disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2076-0817
2076-0817
DOI:10.3390/pathogens7040084